Viz.ai
Headquarters
San Francisco, CAFounded
2016CEO / Founder
Chris MansiEmployees
501-1000Funding
Series D+ — $251MProducts
1 product listedAvg. AI Score
8.0/10Website
viz.ai/
Profile updated
About Viz.ai
Viz.ai is a medical AI company headquartered in San Francisco, California, founded in 2016 by Chris Mansi and David Golan. The company develops software that analyzes medical imaging data and automates care coordination workflows, with a focus on time-critical conditions including stroke, pulmonary embolism, aortic dissection, and cardiac events.
The company's primary product is an FDA-cleared platform that uses AI algorithms to detect abnormalities in CT scans and other imaging studies, then automatically notifies the appropriate specialist via a mobile application. The platform is used by health systems across the United States and Europe to reduce the time between imaging and specialist intervention. Viz.ai has received multiple FDA clearances for its AI algorithms across neurology, cardiology, and vascular disease indications.
Viz.ai has raised approximately $251 million in total funding, including a $100 million Series D round in 2021. The company employs between 500 and 1,000 people and has expanded its platform through partnerships with medical device manufacturers and health systems. In 2021, Viz.ai also received FDA breakthrough device designation for several of its AI-based diagnostic tools.
Specialties
Financials
Dated, source-cited figures. Estimates are marked.
Products by Viz.ai
All products by Viz.ai reviewed by our AI panel of experts.
How Our Review Panel Scores Viz.ai
Six independent reviewer personalities assessed Viz.ai's product on their own terms. They disagreed by 2.4 points — The Finance Lead was the hardest to convince, The Domain Strategist the most positive.
Averaged across 1 reviewed product in our catalog. Scores are out of 10.
Competitive Landscape
Who Viz.ai competes with, and how they differ.
RapidAI (formerly iSchemaView) is Viz.ai's closest head-to-head rival in FDA-cleared large-vessel-occlusion stroke-triage imaging AI, competing hospital-by-hospital for the same neuro-imaging contracts; it remains privately funded on smaller rounds (e.g. a $75M growth round in 2021) versus Viz.ai's roughly $250M raised.
Aidoc runs a broader always-on radiology-AI platform flagging incidental findings (PE, ICH, aneurysm, C-spine fracture) across every CT scan, competing directly with Viz.ai for the same hospital imaging-AI budget rather than Viz.ai's care-coordination-first workflow.
1 product reviewed on TopReviewedQure.ai targets affordable, cloud-based radiology AI (head CT, chest X-ray) for high-volume and emerging-market hospital deployments globally, contrasting with Viz.ai's US-centric, reimbursement-backed (CMS NTAP) premium care-coordination model.
1 product reviewed on TopReviewedHeartFlow's FFR-CT analysis targets outpatient coronary-artery-disease diagnosis from CT angiograms as a non-invasive alternative to catheterization, overlapping with Viz.ai's Cardio Suite in cardiovascular AI but for elective diagnosis rather than acute care coordination.
1 product reviewed on TopReviewedCompany Timeline
Key milestones in Viz.ai's history, with sources.
- Milestone
Viz.ai marks 10 years: 2,000 hospitals, 230M patients, 13 FDA clearances
Company-stated 10th-anniversary milestone: platform live in 2,000+ hospitals, 230 million patients touched, 13 FDA clearances, and first-ever CMS NTAP reimbursement for AI software.
viz.ai - Milestone
FDA clears Viz.ai RV/LV ratio algorithm for pulmonary embolism severity
Viz.ai received FDA 510(k) clearance for an automated RV/LV ratio algorithm that flags right-ventricle dilation to help care teams stratify pulmonary embolism severity.
viz.ai - Funding
Series D — $100M led by Tiger Global and Insight Partners at $1.2B valuation
Viz.ai raised $100 million in a Series D round led by Tiger Global and Insight Partners, becoming a unicorn at a $1.2 billion valuation; Scale Ventures, Kleiner Perkins, Threshold, GV, Sozo Ventures, CRV and Susa also participated.
viz.ai - Milestone
FDA clears Viz.ai algorithm for automated brain aneurysm detection
Viz.ai received FDA 510(k) clearance for Viz Aneurysm, an AI algorithm that flags suspected cerebral aneurysms on CT angiography; validated at 94% accuracy across 528 scans containing 674 aneurysms.
viz.ai - Launch
Viz.ai debuts Viz ANX, first AI-powered cerebral aneurysm detection solution
Viz.ai unveiled Viz ANX at the SVIN 2021 conference, its first AI-powered module for detecting cerebral aneurysms.
viz.ai - Funding
Series C — $71M led by Scale Venture Partners and Insight Partners
Viz.ai raised $71 million in a Series C round led by Scale Venture Partners and Insight Partners, with Greenoaks, Kleiner Perkins, Threshold Ventures, CRV, Innovation Endeavors and Susa Ventures participating; the round brought total funding to over $150 million.
viz.ai - Milestone
CMS grants Viz.ai the first Medicare NTAP for AI software
CMS awarded Viz.ai the first-ever New Technology Add-on Payment (NTAP) for artificial intelligence software, worth up to $1,040 per use for suspected-stroke patients under Medicare's inpatient payment system.
viz.ai - Funding
Series B — $50M led by Greenoaks
Viz.ai raised $50 million in a Series B round led by Greenoaks, with participation from Threshold Ventures, CRV, and existing investors GV and Kleiner Perkins; the platform was live in roughly 300 U.S. hospitals at the time.
massdevice.com - Partnership
Medtronic signs deal to distribute Viz.ai stroke-detection software
Medtronic inked a distribution agreement to sell Viz.ai's LVO stroke-detection AI software, aiming to place it in every U.S. stroke center.
news.medtronic.com - Funding
Series A — $21M with GV (Google Ventures) participating
Viz.ai raised $21 million in a Series A round joined by GV (formerly Google Ventures), funding market expansion beyond stroke care.
massdevice.com - Milestone
FDA grants Viz.ai first-ever De Novo clearance for AI triage software
The FDA granted Viz.ai (device "ContaCT", DEN170073) a De Novo clearance for radiological computer-assisted triage and notification software, the first authorization of an AI clinical-decision-support product for triage.
accessdata.fda.gov - Founded
Viz.ai founded by Chris Mansi and David Golan
Viz.ai was founded in San Francisco by neurosurgeon Dr. Chris Mansi and machine-learning researcher Dr. David Golan to speed AI-driven stroke and care coordination.
viz.ai
Explore AI Software Reviews
Browse multi-perspective AI panel reviews across hundreds of AI tools, agents, and platforms. Find the right software with insights from CTO, Developer, Marketer, Finance, and User perspectives.